Ash R C, Horowitz M M, Gale R P, van Bekkum D W, Casper J T, Gordon-Smith E C, Henslee P J, Kolb H J, Lowenberg B, Masaoka T
International Bone Marrow Transplant Registry, Medical College of Wisconsin, Milwaukee 53226.
Bone Marrow Transplant. 1991 Jun;7(6):443-52.
Results of 470 bone marrow transplants from related donors other than genotypically HLA-identical siblings (alternative related donors) were analysed to identify factors associated with transplant outcome and to determine whether T cell depletion improved results. As compared to 3648 transplant from HLA-identical siblings, alternative related donor transplants were associated with increased graft failure, increased acute graft-versus-host disease (GVHD), and lower disease-free survival. The likelihood of adverse outcome correlated with increasing donor-recipient HLA-disparity. In multivariate analysis of alternative related donor transplants, donor age greater than or equal to 30 years, (relative risk [RR] 1.7, p less than 0.006), intermediate and advanced leukemia (RR 1.5 and 1.6, p less than 0.01 and p less than 0.003), infection pretransplant (RR 1.7, p less than 0.005) and 2- and 3-locus donor-recipient HLA-disparity (RR 1.3, p less than 0.04) were associated with increased risks of treatment failure. The 2-year probability of leukemia-free survival after alternative related donor transplants (n = 43) with none of these adverse prognostic features was 44% (95% confidence interval 28-59%) compared to 56% (95% confidence interval 52-59%) for similar patients receiving HLA-identical sibling transplants (n = 868, univariate p less than 0.03). T cell depletion increased graft failure and decreased acute GVHD after alternative related donor transplants but did not improve leukemia-free survival.
分析了470例来自基因型非HLA完全相同的同胞以外的相关供者(替代相关供者)的骨髓移植结果,以确定与移植结果相关的因素,并确定T细胞清除是否能改善结果。与3648例来自HLA完全相同同胞的移植相比,替代相关供者移植与移植失败增加、急性移植物抗宿主病(GVHD)增加和无病生存率降低相关。不良结果的可能性与供者-受者HLA差异增加相关。在替代相关供者移植的多变量分析中,供者年龄大于或等于30岁(相对风险[RR]1.7,p<0.006)、中晚期白血病(RR 1.5和1.6,p<0.01和p<0.003)、移植前感染(RR 1.7,p<0.005)以及2位点和3位点供者-受者HLA差异(RR 1.3,p<0.04)与治疗失败风险增加相关。没有这些不良预后特征的替代相关供者移植(n = 43)后2年无白血病生存率为44%(95%置信区间28-59%),而接受HLA完全相同同胞移植的类似患者(n = 868,单变量p<0.03)为56%(95%B置信区间52-59%)。T细胞清除增加了替代相关供者移植后的移植失败率并降低了急性GVHD,但未改善无白血病生存率。